1. Metabolic Enzyme/Protease
  2. Aldose Reductase

Aldose Reductase

Aldose reductase is a small, cytosolic, monomeric enzyme which belongs to the aldo-keto reductase superfamily. Aldose reductase catalyzes the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reduction of a wide variety of aromatic and aliphatic carbonyl compounds. It is implicated in the development of diabetic and galactosemic complications involving the lens, retina, nerves, and kidney.

Aldose reductase is both the key enzyme of the polyol pathway, whose activation under hyperglycemic conditions leads to the development of chronic diabetic complications, and the crucial promoter of inflammatory and cytotoxic conditions, even under a normoglycemic status. Aldose reductase represents an excellent drug target and a huge effort is being done to disclose novel compounds able to inhibit it.

Aldose Reductase Related Products (59):

Cat. No. Product Name Effect Purity
  • HY-N0102
    Isoliquiritigenin Inhibitor 98.02%
    Isoliquiritigenin is an anti-tumor flavonoid from the root of Glycyrrhiza uralensis Fisch., which inhibits aldose reductase with an IC50 of 320 nM. Isoliquiritigenin is a potent inhibitor of influenza virus replication with an EC50 of 24.7 μM.
  • HY-N0310
    Soyasaponin Bb Inhibitor 99.13%
    soyasaponin Bb is a soyasaponin isolated from Phaseolus vulgaris, acting as an aldose reductase differential inhibitor (ARDI)[1].
  • HY-105185
    Fidarestat Inhibitor 99.63%
    Fidarestat (SNK 860) is an inhibitor of aldose reductase, with IC50s of 26 nM, 33 μM, and 1.8 μM for aldose reductase, AKR1B10 and V301L AKR1B10, respectively; Fidarestat (SNK 860) has the potential to treat diabetic disease.
  • HY-N0033
    Poliumoside Inhibitor
    Poliumoside, a caffeoylated phenylpropanoid glycoside, is isolated from Brandisia hancei stems and leaves. Poliumoside is an advanced glycation end product (AGE) formation and rat lens aldose reductase (RLAR) inhibitor, with IC50s of 19.69 and 8.47 μM, respectively. Poliumoside also has antiinflammatory and antioxidant activity[1][2][3].
  • HY-66009
    Epalrestat Inhibitor 99.72%
    Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy[1][2][3].
  • HY-118819
    5-Bromo-3-phenyl salicylic acid Inhibitor
    5-Bromo-3-phenyl salicylic acid is a selective inhibitor for human 20α-hydroxysteroid dehydrogenase (AKR1C1) with Ki of 140 nM[1].
  • HY-162325
    WJ-39 Inhibitor
    WJ-39 is an orally active aldose reductase (AR) inhibitor. WJ-39 improves tubular damage in diabetic nephropathy rats by activating PINK1/Parkin signaling, promoting mitophagy, and attenuating apoptosis[1].
  • HY-161472
    Aldose reductase-IN-7 Inhibitor
    Aldose reductase-IN-7 (Compound 6k) targets Aldose reductase. Aldose reductase-IN-7 exhibits potent enzyme inhibitory activity (Ki = 0.186 ± 0.020 μM), showing superiority to Epalrestat (HY-66009), which is currently in clinical use. Aldose reductase-IN-7 is less cytotoxic and possesses potent anticancer activity[1].
  • HY-106198
    Lidorestat Inhibitor 99.50%
    Lidorestat (IDD-676) is a potent, selective and orally active aldose reductase inhibitor with an IC50 of 5 nM. Lidorestat can be used for chronic diabetes complications. Lidorestat also improves nerve conduction and reduces cataract formation[1][2][3].
  • HY-120208
    MK204 Inhibitor
    MK204 is an aldose reductase (AR) inhibitor that can be used in diabetes research[1].
  • HY-151231
    6-Hydroxyluteolin Inhibitor
    6-Hydroxyluteolin (Compound 17) is a flavonoid compound. 6-Hydroxyluteolin has an inhibitory effect on aldose reductase (AR) [1].
  • HY-15314
    Ranirestat Inhibitor
    Ranirestat (AS-3201) potent and orally active aldose reductase (AR) inhibitor with IC50s of 11 nM and 15 nM for rat lens AR and recombinant human AR, respectively, and a Ki of 0.38 nM for recombinant human AR. Ranirestat has the potential for diabetic sensorimotor polyneuropathy treatment. Ranirestat also has a neuroprotective effect on diabetic retinas[1][2].
  • HY-139696
    AKR1B10-IN-1 Inhibitor
    AKR1B10-IN-1 is a potent inhibitor of AKR1B10 (Aldo-Keto Reductase 1B10) with an IC50 of 3.5 nM. AKR1B10-IN-1 suppresses proliferation, metastasis, and Cisplatin (CDDP) resistance of lung cancer cells[1].
  • HY-N1517
    Ganoderic acid C2 99.30%
    Ganoderic acid C2 is a bioactive triterpenoid in Ganoderma lucidum. Ganoderic acid C2 possesses the potential anti-tumor bioactivity, antihistamine, anti-aging and cytotoxic effects. Ganoderic acid C2 exhibits high inhibitory activity against the rat lens aldose reductase (RLAR) with an IC50 of 3.8 µM[1][2].
  • HY-N7962
    Cornoside Inhibitor
    Cornoside is a phenolic glycoside and has inhibitory effect on rat lens aldose reductase (AR) with an IC50 of 150 μM[1].
  • HY-149254
    PTP1B/AKR1B1-IN-1 Inhibitor
    PTP1B/AKR1B1-IN-1 is a dual inhibitor of protein tyrosine phosphatase 1B (PTP1B) and aldose reductase (AKR1B1), with IC50s of 0.06 μM and 4.3 μM, respectively. PTP1B/AKR1B1-IN-1 also inhibits TC-PTP with an IC50 value of 9 μM. PTP1B/AKR1B1-IN-1 serves as an insulin-mimetic agent in murine myoblasts, and reduces AKR1B1-dependent sorbitol accumulation. PTP1B/AKR1B1-IN-1 inhibits development of type 2 diabetes mellitus (T2DM) to control blood glucose levels[1].
  • HY-121933
    IDD388 Inhibitor
    IDD388 is a selective aldose reductase (ALR2) inhibitor with an IC50 of 30 nM. IDD388 displays selectivity for ALR2 over ALR1 (IC50 of 14 μM)[1].
  • HY-151947
    ALR2-IN-3 Inhibitor
    ALR2-IN-2 is a potent inhibitor of aldose reductase (ALR2), with IC50s of 22 nM and 116 nM for rat ALR2 and ALR1, respectively. ALR2-IN-2 can be used for the research of diabetic complications[1].
  • HY-N4089
    Quercetin 3-gentiobioside Inhibitor
    Quercetin 3-gentiobioside is isolated from A. iwayomogi, AR and AGE formation inhibitor, demonstrates biological activities against Aldose reductase (AR) and the formation of advanced glycation endproducts (AGEs)[1].
  • HY-131542
    APPA Inhibitor
    APPA is an aldose reductase inhibitor. APPA can effectively prevent apoptosis and the symptoms of Streptozotocin (HY-13753)-induced diabetes by inhibiting the polyol pathway in rats. APPA has the potential for diabetic nephropathy (DN) research[1].